CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Tolvaptan (Jynarque) for autosomal dominant polycystic kidney disease (ADPKD) — Coverage Criteria

Covers clinical criteria, documentation, and authorization rules for Jynarque (tolvaptan) to slow kidney function decline in adults with rapidly progressing ADPKD for Neighborhood Health Plan of Rhode Island Medicaid members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyTolvaptan (Jynarque) for ADPKD — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateApr 1, 2020

Next Review DateN/A

Key ActionObtain prior authorization and documentation (including imaging or genetic results) with nephrologist involvement for initial 6‑month approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsauthorization length

eGFR ≥ 25eligibility eGFR

1 tablet/daydispensing restriction

Adultsindicated age group

Coverage Criteria for Tolvaptan (Jynarque)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Approval

Covered when ALL of the following are met:

Initial approval: 1) Member is 18 years of age or older with a diagnosis of autosomal dominant polycystic kidney disease (ADPKD).

Authorization period: 6 months

Imaging/genetic confirmation: 2) Member is at risk for rapidly progressing disease confirmed by imaging (including age‑adjusted cyst count criteria or height‑adjusted total kidney volume compatible with Mayo classification), genetic testing (PKD1 or PKD2 mutation), or family history criteria (e.g., specified cyst counts by age with a first‑degree relative with ADPKD).

Renal function: 3) Estimated glomerular filtration rate (eGFR) is greater than or equal to 25 mL/min/1.73 m2.>= 25 mL/min/1.73 m2

Prescriber: 4) Prescribed by, or in consultation with, a nephrologist or physician specializing in the management of ADPKD.

Contraindications: 5) No contraindications present, including significant liver impairment or injury, concurrent use of strong CYP3A4 inhibitors, inability to sense or respond to thirst, abnormal serum sodium (particularly hypernatremia), hypovolemia, concomitant diuretic use, or uncorrected urinary outflow obstruction.

Continuation of Therapy

Covered when ALL of the following are met:

Continuation approval: 1) Member was previously authorized for an indication meeting Initial Approval criteria.

Renewal authorization: 6 months

Clinical benefit: 2) Member has demonstrated clinical benefit (for example, slowed decline in kidney function or decreased pain).

Documentation of benefit required

Renal function maintained: 3) eGFR remains greater than or equal to 25 mL/min/1.73 m2.>= 25 mL/min/1.73 m2

Authorization period: 4) Renewal is authorized for 6 months when the above conditions are met.

Coverage for tolvaptan (Jynarque) is provided when all criteria for the FDA‑approved indication are met. Specifically, authorization may be granted for adults with a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) who are at risk for rapidly progressing disease and who satisfy diagnostic and safety requirements. Initial approvals are issued for 6 months when the member meets diagnostic criteria (e.g., imaging or genetic/family history confirmation of risk for rapid progression), has preserved renal function at or above the policy threshold of eGFR ≥ 25 mL/min/1.73 m2, and has no contraindications that would preclude therapy. Continuation authorizations are also granted for 6 months provided documentation of clinical benefit and maintenance of an eGFR ≥ 25 mL/min/1.73 m2.

Product Formulations, Quantity Limits, and Thresholds

Covered NDC/FormulationsNDCCovered

Jynarque 15-15mg	tolvaptan 15 mg tablets (packaged as 15 mg)
Jynarque 30-15mg	tolvaptan 30 mg (15 mg tablets, 30 mg pack)
Jynarque 45-15mg	tolvaptan 45 mg (15 mg tablets, 45 mg pack)
Jynarque 60-30mg	tolvaptan 60 mg (30 mg tablets, 60 mg pack)
Jynarque 90-30mg	tolvaptan 90 mg (30 mg tablets, 90 mg pack)

Quantity Limitsmixed

QTY	Maximum 2 tablets of Jynarque per day (combined across formulations).
PAK_DAY	Limit of 1 tablet per pak day as packaged (pack-level administration constraint).

Dose Clarificationmixed

DAILY_DOSE

Typical dosing uses 15 mg and 30 mg tablets; quantity limits apply across all listed formulations.

eGFR Threshold

Minimum eGFR>= 25 mL/min/1.73 m^2

Provider Requirements, Documentation, and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization required. Jynarque (tolvaptan) requires prior authorization before initiation. Initial approvals are for up to 6 months; continuation requires reauthorization with documentation of clinical benefit and monitoring per policy.

Initial approval duration: up to 6 months
Prior authorization required for all members prior to Jynarque initiation

Note

Provider Action (High Importance)

Provider action: Prescriptions must be initiated by, or in consultation with, a nephrologist or a physician who specializes in the management of ADPKD. Ensure prior authorization is submitted with all required documentation to avoid delays or denials.

Prescriber requirement: nephrologist or ADPKD specialist (or documented consultation)

Documentation Required

Required Clinical Documentation

Required clinical documentation: Submit documentation to support a diagnosis of ADPKD and risk of rapidly progressing disease. Authorization review will not proceed without the items below.

Genetic testing results, if applicable (e.g., PKD1 or PKD2 mutation reports)
Imaging used for diagnosis and confirmation of rapidly progressing disease (ultrasound, MRI, or CT) including height-adjusted total kidney volume (Mayo classification) when available
Relevant laboratory results including baseline and follow-up eGFR and liver function tests (LFTs)
Documentation of symptoms or objective measures indicating risk of rapidly progressing ADPKD (e.g., TKV, family history, number of cysts by age criteria)

Denial Risk

Experimental / Not Medically Necessary Uses

Non‑FDA/Non‑compendial indications: Use of Jynarque for any indication other than to slow kidney function decline in adults at risk of rapidly progressing ADPKD is considered experimental/investigational and is not covered.

Only FDA‑approved indication (ADPKD at risk of rapid progression) is covered; all other uses are not medically necessary

Denial Risk

Contraindications / High Risk for Denial

Contraindications and denial risks: Requests will be denied or considered contraindicated for members with specified conditions or medication interactions. Review contraindications carefully prior to submission.

Estimated GFR < 25 mL/min/1.73 m2 — not eligible
Significant liver impairment or history of liver injury — contraindication
Concurrent use of strong CYP3A4 inhibitors — contraindication
Inability to sense or respond to thirst, hypernatremia, hypovolemia, concomitant use of diuretics without appropriate management, or uncorrected urinary outflow obstruction — contraindications

Background

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by progressive renal cyst growth leading to decline in kidney function. Tolvaptan (Jynarque) is a vasopressin V2 receptor antagonist indicated to slow kidney function decline in adults who are at risk of rapidly progressing ADPKD. Assessment of risk for rapid progression may involve imaging measures (including height‑adjusted total kidney volume consistent with Mayo classification), genetic testing for PKD1/PKD2 mutations, or relevant family history; safety considerations include baseline and ongoing assessment of liver function and renal function (eGFR).

Definitions

Rapidly progressing ADPKD — defining criteria

Primary imaging criterionHeight‑adjusted total kidney volume (htTKV) compatible with Mayo classification indicating rapidly progressing disease

Genetic/family supporting criteriaPresence of PKD1 or PKD2 mutation or family history consistent with ADPKD may support risk for rapid progression

Age‑and‑imaging criteriaRadiologic cyst criteria by age (e.g., ≥3 cysts for ages 18–<40 with affected first‑degree relative; age‑specific cyst thresholds apply) used in diagnosis and assessment of progression risk

Documentation requiredImaging reports (ultrasound, CT, or MRI) and genetic testing results if applicable to confirm rapidly progressing disease